This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
A synthetic GHRH analogue — FDA-approved as Egrifta for visceral fat reduction in HIV-associated lipodystrophy. More potent and longer-acting than sermorelin. Stimulates pulsatile GH release while preserving the pituitary feedback loop, with emerging research in cognitive function and general body composition.
Tesamorelin is the full 44-amino acid GHRH analogue (GHRH 1-44) with a trans-3-hexenoic acid modification at the N-terminus that increases stability and bioavailability compared to native GHRH. This is the molecule behind Egrifta — FDA-approved in 2010 for HIV-associated lipodystrophy, specifically the excess visceral abdominal fat accumulation that occurs with antiretroviral therapy.
Unlike sermorelin (GHRH 1-29), tesamorelin is the full-length analogue and demonstrates more robust and sustained GH stimulation in clinical trials. Like sermorelin, it works by stimulating GH release from the pituitary — preserving the hypothalamic-pituitary feedback loop and natural pulsatility, not bypassing it as exogenous GH does.
Beyond its approved indication, tesamorelin is actively studied for age-related body composition changes, visceral fat accumulation in non-HIV populations, and cognitive function — particularly in older adults and those with mild cognitive impairment.
Phase III clinical trials showed 15–20% reduction in trunk/visceral adipose tissue (VAT) after 6 months of 2mg daily dosing in HIV+ patients. Effect is driven by GH-mediated lipolysis in visceral fat depots.
Improved lean-to-fat ratio, reduced trunk fat, improved IGF-1 levels. Research in non-HIV aging populations is ongoing — visceral fat accumulation is a near-universal feature of aging independent of HIV status.
Human studies at UCSF and other institutions show improvements in cognitive test performance in older adults on tesamorelin — particularly in executive function and verbal memory. GH/IGF-1 have established roles in neuronal maintenance.
Unlike exogenous GH (which suppresses endogenous production), tesamorelin stimulates the pituitary to release GH in its natural pulsatile pattern. Negative feedback remains intact — a safety advantage for long-term research use.
Visceral fat reduction is associated with improved lipid profiles and inflammatory markers. Tesamorelin studies have shown improvements in triglycerides and markers of metabolic syndrome in treated patients.
Tesamorelin reliably elevates IGF-1 levels — the downstream mediator of many GH effects on muscle, bone, and cognition. IGF-1 normalization is a common research endpoint and clinical marker of treatment response.
The FDA-approved dose is 2mg SC daily (abdominal injection). Research protocols for body composition and cognitive function in aging populations have used the same dose. Administered at bedtime to align with the natural nocturnal GH pulse.
| Protocol | Dose | Frequency | Notes |
|---|---|---|---|
| Standard | 2mg SC | Daily at bedtime | FDA-approved dose. Bedtime administration aligns with natural GH pulsatility — the largest GH pulse in healthy individuals occurs in the first hours of sleep. |
| Lower range | 1mg SC | Daily | Some researchers use 1mg to reduce IGF-1 elevation while still achieving meaningful GH stimulation. Less studied but used in practice. |
| Cycle length | — | 3–6 months | Clinical trials used 6-month protocols. Cycling is recommended to allow IGF-1 levels to normalize and assess ongoing response. IGF-1 monitoring is advisable during longer protocols. |
CT-confirmed VAT reduction at 26 weeks in Phase III Study 1: −27 cm² on tesamorelin vs +4 cm² on placebo. Study 2 showed −14% (−21 cm²). Combined treatment difference of approximately 30 cm².
Two randomized, double-blind, placebo-controlled Phase III trials enrolled 543 tesamorelin-treated patients. Among the largest controlled GHRH datasets, with extension phases out to 52 weeks.
Egrifta received FDA approval for HIV-associated lipodystrophy — giving tesamorelin one of the strongest regulatory track records of any GHRH compound. Re-approved in updated formulation as Egrifta SV (2019).
At 26 weeks, 47% of tesamorelin patients had IGF-1 SDS >2 (above age-adjusted normal). Underscores the need for baseline and periodic IGF-1 monitoring — supraphysiologic levels warrant dose review.
Tesamorelin's FDA approval required two full Phase III trials, which means the adverse event data is unusually detailed for a peptide compound. The profile is well-characterized. Key signals from the Phase III dataset (543 treated patients, 26-week primary endpoint):
17% on tesamorelin vs 6% on placebo. Erythema, pruritus, and induration at the subcutaneous injection site. Rotating injection sites (abdominal regions) reduces frequency. Generally mild and self-limiting.
13% on tesamorelin vs 11% on placebo. A known effect of GH-axis stimulation — GH promotes joint fluid and tissue growth. Usually mild. Monitor in patients with pre-existing joint conditions. Dose reduction resolves most cases.
6% on tesamorelin vs 2% on placebo. Fluid retention is a GH-axis class effect — IGF-1 promotes sodium retention. Usually transient and resolves with continued use. Significant edema warrants protocol pause and evaluation.
5% on tesamorelin vs 2% on placebo. Tingling or numbness in extremities — a recognized GH-axis effect linked to peripheral nerve swelling. Typically transient. Persistent paresthesia warrants dose reduction or carpal tunnel evaluation.
5% of tesamorelin patients vs 1% placebo developed HbA1c ≥6.5% (hazard ratio 3.3; 95% CI 1.4–9.6). GH is insulin-antagonistic. Screen HbA1c and fasting glucose at baseline. Patients with pre-diabetes or diabetes require closer metabolic monitoring during protocol.
Active malignancy (GH stimulation may promote tumor growth), disruption of hypothalamic-pituitary axis (tumor, trauma, surgery, radiation), confirmed hypersensitivity to tesamorelin, pregnancy. IGF-1 above 3 SDS warrants protocol pause pending evaluation.
Baseline labs recommended before starting: fasting glucose, HbA1c, IGF-1, and a general metabolic panel. Repeat IGF-1 at 6–8 weeks, then every 3–6 months on extended protocols. Anti-tesamorelin IgG antibodies develop in approximately 50% of long-term patients; clinical significance remains unclear in the published literature.
Tesamorelin is a GHRH analogue — do not combine with other GHRH peptides (sermorelin, CJC-1295). Combining two GHRH agonists does not produce additive benefit and may desensitize receptors. GHRP pairing (ipamorelin) is acceptable and amplifies the GH pulse via a different receptor:
Do not combine with Sermorelin or CJC-1295 — overlapping GHRH receptor activity without additive benefit.
Third-party COA, Finnrick-verified purity. Available in 10mg and 20mg vials. Ships within 24 hours.
Start Protocol Intake ← All ProtocolsMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.